Drug Profile
Anti interleukin-2 receptor monoclonal antibody - National Institute of Health/Roche
Alternative Names: Anti-CD122 monoclonal antibody Mikβ1; HuMikβ1-1; Interleukin-2 receptor beta monoclonal antibody Mikβ1; Mikβ1Latest Information Update: 16 May 2019
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA)
- Developer National Institutes of Health (USA); Roche
- Class Monoclonal antibodies
- Mechanism of Action Interleukin 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 16 May 2019 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
- 06 Aug 1998 No-Development-Reported for Transplant rejection in USA (Unknown route)
- 25 Mar 1996 New profile